Reducing the global burden of cardiovascular disease, part 1: The epidemiology and risk factors

Circulation Research

Volumn 121, Issue 6, 2017, Pages 677-694

  Joseph, Philip ^a   Leong, Darryl ^a   McKee, Martin ^b   Anand, Sonia S ^a   Schwalm, Jon David ^a   Teo, Koon ^a   Mente, Andrew ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Blood pressure; Cardiovascular diseases; Epidemiology; Risk factors; Tobacco

Indexed keywords

CHOLESTEROL; SODIUM;

AIR POLLUTION; ALCOHOL CONSUMPTION; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIET; DISEASE BURDEN; ELEVATED BLOOD PRESSURE; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; FEEDING BEHAVIOR; FOOD; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEART FAILURE; HUMAN; INDOOR AIR POLLUTION; ISCHEMIC HEART DISEASE; NUTRIENT; OBESITY; OUTDOOR AIR POLLUTION; PHYSICAL INACTIVITY; PRIORITY JOURNAL; REVIEW; RHEUMATIC HEART DISEASE; SMOKING REGULATION; TOBACCO USE; CARDIOVASCULAR DISEASES; GLOBAL DISEASE BURDEN;

CARDIOVASCULAR DISEASES; GLOBAL BURDEN OF DISEASE; HUMANS;

EID: 85028858468     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.308903     Document Type: Review

References (115)

1. Omran AR. The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49:509-538.
2. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYS) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1603-1658. doi: 10.1016/S0140-6736(16)31460-X.
3. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459-1544.
4. World Health Organization. Who Global NCD Action Plan 2013-2020. Geneva, Switzerland: WHO; 2013.
5. Bonita R, Magnusson R, Bovet P, Zhao D, Malta DC, Geneau R, Suh I, Thankappan KR, McKee M, Hospedales J, de Courten M, Capewell S, Beaglehole R; Lancet NCD Action Group. Country actions to meet UN commitments on non-communicable diseases: a stepwise approach. Lancet. 2013;381:575-584. doi: 10.1016/S0140-6736(12)61993-X.
6. Griggs D, Stafford-Smith M, Gaffney O, Rockström J, Ohman MC, Shyamsundar P, Steffen W, Glaser G, Kanie N, Noble I. Policy: sustainable development goals for people and planet. Nature. 2013;495:305-307. doi: 10.1038/495305a.
7. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009;158:1-7.e1. doi: 10.1016/j.ahj.2009.04.019.
8. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1-25. doi: 10.1016/j.jacc.2017.04.052.
9. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372:1333-1341. doi: 10.1056/NEJMoa1406656.
10. Norheim OF, Jha P, Admasu K, et al. Avoiding 40% of the premature deaths in each country, 2010-30: review of national mortality trends to help quantify the UN sustainable development goal for health. Lancet. 2015;385:239-252. doi: 10.1016/S0140-6736(14)61591-9.
11. Centers for Disease Control and Prevention. Decline in deaths from heart disease and stroke-United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48:649-656.
12. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129:1493-1501. doi: 10.1161/CIRCULATIONAHA.113.004046.
13. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, Naghavi M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129:1483-1492. doi: 10.1161/CIRCULATIONAHA.113.004042.
14. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.
15. Krishnamurthi RV, Feigin VL, Forouzanfar MH et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet Glob Health. 2013;1:e259-e281.
16. Chiu D, Peterson L, Elkind MS, Rosand J, Gerber LM, Silverstein MD; Glycine Antagonist in Neuroprotection Americas Trial Investigators. Comparison of outcomes after intracerebral hemorrhage and ischemic stroke. J Stroke Cerebrovasc Dis. 2010;19:225-229. doi: 10.1016/j.jstrokecerebrovasdis.2009.06.002.
17. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646-659. doi: 10.1161/CIRCRESAHA.113.300268.
18. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Failure: 2014;1; 4-25.
19. Sato N. Epidemiology of heart failure in Asia. Heart Fail Clin. 2015;11:573-579. doi: 10.1016/j.hfc.2015.07.009.
20. Dokainish H, Teo K, Zhu J, et al; INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health. 2017;5:e665-e672. doi: 10.1016/S2214-109X(17)30196-1.
21. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. doi: 10.1161/CIRCULATIONAHA.113.005119.
22. Zühlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. Glob Heart. 2013;8:189-195. doi: 10.1016/j.gheart.2013.08.008.
23. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol. 2011;3:67-84. doi: 10.2147/CLEP.S12977.
24. Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127:749-756. doi: 10.1161/CIRCULATIONAHA.112.128413.
25. Engel LW, Strauchen JA, Chiazze L Jr, Heid M. Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases. Am J Epidemiol. 1980;111:99-112.
26. Ram U, Jha P, Gerland P, Hum RJ, Rodriguez P, Suraweera W, Kumar K, Kumar R, Dikshit R, Xavier D, Gupta R, Gupta PC, Ram F. Age-specific and sex-specific adult mortality risk in India in 2014: analysis of 0.27 million nationally surveyed deaths and demographic estimates from 597 districts. Lancet Glob Health. 2015;3:e767-e775.
27. Murray CJ, Lozano R, Flaxman AD, et al. Using verbal autopsy to measure causes of death: the comparative performance of existing methods. BMC Med. 2014;12:5. doi: 10.1186/1741-7015-12-5.
28. Moran AE, Oliver JT, Mirzaie M, et al. Assessing the global burden of ischemic heart disease: part 1: methods for a systematic review of the global epidemiology of ischemic heart disease in 1990 and 2010. Glob Heart. 2012;7:315-329. doi: 10.1016/j.gheart.2012.10.004.
29. Bambra C, Gibson M, Sowden A, Wright K, Whitehead M, Petticrew M. Tackling the wider social determinants of health and health inequalities: evidence from systematic reviews. J Epidemiol Community Health. 2010;64:284-291. doi: 10.1136/jech.2008.082743.
30. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. doi: 10.1016/S0140-6736(04)17018-9.
31. O'Donnell MJ, Chin SL, Rangarajan S, et al; INTERSTROKE Investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761-775. doi: 10.1016/S0140-6736(16)30506-2.
32. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002.
33. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172:1386-1394. doi: 10.1001/archinternmed.2012.3310.
34. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501-1508. doi: 10.1161/CIRCULATIONAHA.110.009035.
35. Lonn EM, Bosch J, López-Jaramillo P, et al; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-2020. doi: 10.1056/ NEJMoa1600175.
36. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717.
37. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-2031. doi: 10.1056/NEJMoa1600176.
38. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-2561. doi: 10.1016/S0140-6736(16)31357-5.
39. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722. doi: 10.1056/NEJMoa1615664.
40. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368:647-658. doi: 10.1016/S0140-6736(06)69249-0.
41. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005;111:2684-2698. doi: 10.1161/CIRCULATIONAHA.104.492215.
42. Hom S, Chen L, Wang T, Ghebrehiwet B, Yin W, Rubenstein DA. Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of electronic cigarette extracts of variable nicotine concentrations. Platelets. 2016;27:694-702. doi: 10.3109/09537104.2016.1158403.
43. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, Wollum A, Sanman E, Wulf S, Lopez AD, Murray CJ, Gakidou E. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311:183-192. doi: 10.1001/jama.2013.284692.
44. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
45. Wright JT, Jr., Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116.
46. NCDRF Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37-55.
47. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S; INTERHEART Study Investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224-233. doi: 10.1016/S0140-6736(08)61076-4.
48. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol). National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011;377:578-586. doi: 10.1016/S0140-6736(10)62038-7.
49. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545-1602
50. NCDRF Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513-1530.
51. Berrington de Gonzalez A, Hartge P et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-2219.
52. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all cause mortality: systematic review and nonlinear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.
53. NCDRF Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 populationbased measurement studies with 19.2 million participants. Lancet. 2016;387:1377-1396.
54. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U; Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380:247-257. doi: 10.1016/S0140-6736(12)60646-1.
55. Department of Health. Alcohol Guidelines Review - Report from the Guidelines Development Group to the UK Chief Medical Officers. London, United Kingdom: Department of Health; 2016.
56. Smyth A, Teo KK, Rangarajan S, et al; PURE Investigators. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. Lancet. 2015;386:1945-1954. doi: 10.1016/S0140-6736(15)00235-4.
57. Toma A, Paré G, Leong DP. Alcohol and cardiovascular disease: how much is too much? Curr Atheroscler Rep. 2017;19:13. doi: 10.1007/s11883-017-0647-0.
58. McKee M, Britton A. The positive relationship between alcohol and heart disease in eastern Europe: potential physiological mechanisms. J R Soc Med. 1998;91:402-407.
59. Leong DP, Smyth A, Teo KK, McKee M, Rangarajan S, Pais P, Liu L, Anand SS, Yusuf S; INTERHEART Investigators. Patterns of alcohol consumption and myocardial infarction risk: observations from 52 countries in the INTERHEART case-control study. Circulation. 2014;130:390-398. doi: 10.1161/CIRCULATIONAHA.113.007627.
60. Gmel G, Labhart F, Shield, K, Rylett M, Lachenmeier, D, Rehm, J. A Global overview of alcohol consumption patterns. In: Boyle P, ed. Alcohol Science, Policy and Public Health. Oxford, United Kingdom: Oxford University Press; 2013:115-124.
61. O'Donnell M, Mann JF, Schutte AE, Staessen JA, Lopez-Jaramillo P, Thomas M, Mente A, Saulnier PJ, Yusuf S. Dietary sodium and cardiovascular disease risk. N Engl J Med. 2016;375:2404-2406. doi: 10.1056/NEJMc1612304.
62. Mente A, O'Donnell M, Rangarajan S, et al; PURE, EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet. 2016;388:465-475. doi: 10.1016/S0140-6736(16)30467-6.
63. Heaney RP. Sodium: how and how not to set a nutrient intake recommendation. Am J Hypertens. 2013;26:1194-1197. doi: 10.1093/ajh/hpt130.
64. Graudal N, Jürgens G, Baslund B, Alderman MH. Compared with usual sodium intake, low-and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens. 2014;27:1129-1137. doi: 10.1093/ajh/hpu028.
65. Oparil S. Low sodium intake-cardiovascular health benefit or risk? N Engl J Med. 2014;371:677-679. doi: 10.1056/NEJMe1407695.
66. Mancia G, Oparil S, Whelton PK, McKee M, Dominiczak A, Luft FC, AlHabib K, Lanas F, Damasceno A, Prabhakaran D, La Torre G, Weber M, O'Donnell M, Smith SC, Narula J. The technical report on sodium intake and cardiovascular disease in low-and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. Eur Heart J. 2017;38:712-719. doi: 10.1093/eurheartj/ehw549.
67. de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, Uleryk E, Budylowski P, Schünemann H, Beyene J, Anand SS. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015;351:h3978.
68. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr. 2008;87:627-637.
69. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016;133:187-225. doi: 10.1161/CIRCULATIONAHA.115.018585.
70. Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore H, Davey Smith G. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev. 2011:CD002137.
71. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655-666. doi: 10.1001/jama.295.6.655.
72. Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490.
73. Du H, Li L, Bennett D, et al; China Kadoorie Biobank Study. Fresh fruit consumption and major cardiovascular disease in China. N Engl J Med. 2016;374:1332-1343. doi: 10.1056/NEJMoa1501451.
74. Micha R, Michas G, Mozaffarian D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes-an updated review of the evidence. Curr Atheroscler Rep. 2012;14:515-524. doi: 10.1007/s11883-012-0282-8.
75. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024-1033. doi: 10.1001/2012.jama.11374.
76. Malik VS, Popkin BM, Bray GA, Després JP, Hu FB. Sugarsweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation. 2010;121:1356-1364. doi: 10.1161/CIRCULATIONAHA.109.876185.
77. Huang C, Huang J, Tian Y, Yang X, Gu D. Sugar sweetened beverages consumption and risk of coronary heart disease: a meta-analysis of prospective studies. Atherosclerosis. 2014;234:11-16. doi: 10.1016/j.atherosclerosis.2014.01.037.
78. Estruch R, Ros E, Salas-Salvadó J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290. doi: 10.1056/NEJMoa1200303.
79. Anand SS, Hawkes C, de Souza RJ, et al. Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: a report from the workshop convened by the World Heart Federation. J Am Coll Cardiol. 2015;66:1590-1614. doi: 10.1016/j.jacc.2015.07.050.
80. Brook RD, Rajagopalan S, Pope CA 3rd, et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation. 2014;129:562-569.
81. Di Q, Wang Y, Zanobetti A, Wang Y, Koutrakis P, Choirat C, Dominici F, Schwartz JD. Air pollution and mortality in the medicare population. N Engl J Med. 2017;376:2513-2522.
82. Mitter SS, Vedanthan R, Islami F, Pourshams A, Khademi H, Kamangar F, Abnet CC, Dawsey SM, Pharoah PD, Brennan P, Fuster V, Boffetta P, Malekzadeh R. Household fuel use and cardiovascular disease mortality: Golestan Cohort Study. Circulation. 2016;133:2360-2369. doi: 10.1161/CIRCULATIONAHA.115.020288.
83. Lu F, Xu D, Cheng Y, Dong S, Guo C, Jiang X, Zheng X. Systematic review and meta-analysis of the adverse health effects of ambient PM2.5 and PM10 pollution in the Chinese population. Environ Res. 2015;136:196-204. doi: 10.1016/j.envres.2014.06.029.
84. Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries. A critical challenge to achieve global health. In: Fuster V, Kelly BB, eds. Promoting Cardiovascular Health in the Developing World. Washington, DC: National Academies Press; 2010.
85. GBD 2015 Healthcare Access and Quality Collaborators. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the global burden of disease study 2015. Lancet. 2017;390:231-266. doi: 10.1016/s0140-6736(1017)30818-30818
86. Yusuf S, Rangarajan S, Teo K, et al; PURE Investigators. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371:818-827. doi: 10.1056/NEJMoa1311890.
87. Chow CK, Teo KK, Rangarajan S, et al; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and lowincome countries. JAMA. 2013;310:959-968. doi: 10.1001/jama.2013.184182.
88. Mohanan PP, Mathew R, Harikrishnan S, Krishnan MN, Zachariah G, Joseph J, Eapen K, Abraham M, Menon J, Thomas M, Jacob S, Huffman MD, Prabhakaran D; Kerala ACS Registry Investigators. Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. Eur Heart J. 2013;34:121-129. doi: 10.1093/eurheartj/ehs219.
89. Yusuf S, Islam S, Chow CK, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middleincome, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243. doi: 10.1016/S0140-6736(11)61215-4.
90. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J. 2013;34:1262-1269. doi: 10.1093/eurheartj/ehs481.
91. Khatib R, Schwalm JD, Yusuf S, Haynes RB, McKee M, Khan M, Nieuwlaat R. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One. 2014;9:e84238. doi: 10.1371/journal.pone.0084238.
92. Adler AJ, Prabhakaran D, Bovet P, Kazi DS, Mancia G, Mungal-Singh V, Poulter N. Reducing cardiovascular mortality through prevention and management of raised blood pressure: a World Heart Federation Roadmap. Glob Heart. 2015;10:111-122. doi: 10.1016/j.gheart.2015.04.006.
93. Balabanova D, McKee M, Mills A, Walt G, Haines A. What can global health institutions do to help strengthen health systems in low income countries? Health Res Policy Syst. 2010;8:22. doi: 10.1186/1478-4505-8-22.
94. Khatib R, McKee M, Shannon H, et al; PURE Study Investigators. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387:61-69. doi: 10.1016/S0140-6736(15)00469-9.
95. Sallis JF, Floyd MF, Rodríguez DA, Saelens BE. Role of built environments in physical activity, obesity, and cardiovascular disease. Circulation. 2012;125:729-737. doi: 10.1161/CIRCULATIONAHA.110.969022.
96. Boehmer TK, Hoehner CM, Deshpande AD, Brennan Ramirez LK, Brownson RC. Perceived and observed neighborhood indicators of obesity among urban adults. Int J Obes (Lond). 2007;31:968-977. doi: 10.1038/sj.ijo.0803531.
97. Librett JJ, Yore MM, Schmid TL. Characteristics of physical activity levels among trail users in a U.S. national sample. Am J Prev Med. 2006;31:399-405. doi: 10.1016/j.amepre.2006.07.009.
98. Garfinkel-Castro A, Kim K, Hamidi S, Ewing R. Obesity and the built environment at different urban scales: examining the literature. Nutr Rev. 2017;75:51-61. doi: 10.1093/nutrit/nuw037.
99. Durand CP, Andalib M, Dunton GF, Wolch J, Pentz MA. A systematic review of built environment factors related to physical activity and obesity risk: implications for smart growth urban planning. Obes Rev. 2011;12:e173-e182. doi: 10.1111/j.1467-789X.2010.00826.x.
100. Rosen L, Rosenberg E, McKee M, Gan-Noy S, Levin D, Mayshar E, Shacham G, Borowski J, Nun GB, Lev B; Healthy Israel 2020 Tobacco Control Subcommittee. A framework for developing an evidencebased, comprehensive tobacco control program. Health Res Policy Syst. 2010;8:17. doi: 10.1186/1478-4505-8-17.
101. Levy DT, Meza R, Zhang Y, Holford TR. Gauging the effect of U.S. tobacco control policies from 1965 through 2014 using SimSmoke. Am J Prev Med. 2016;50:535-542. doi: 10.1016/j.amepre.2015.10.001.
102. Levy D, de Almeida LM, Szklo A. The Brazil SimSmoke policy simulation model: the effect of strong tobacco control policies on smoking prevalence and smoking-attributable deaths in a middle income nation. PLoS Med. 2012;9:e1001336. doi: 10.1371/journal.pmed.1001336.
103. MPOWER in Action. Defeating the global tobacco epidemic. Available at: http://www.who.int/tobacco/mpower/publications/mpower-2013.pdf?ua=1. Accessed: August 16, 2017.
104. Peeters S, Costa H, Stuckler D, McKee M, Gilmore AB. The revision of the 2014 European tobacco products directive: an analysis of the tobacco industry's attempts to 'break the health silo'. Tob Control. 2016;25:108-117. doi: 10.1136/tobaccocontrol-2014-051919.
105. Bogdanovica I, McNeill A, Murray R, Britton J. What factors influence smoking prevalence and smoke free policy enactment across the European Union Member States. PLoS One. 2011;6:e23889. doi: 10.1371/journal.pone.0023889.
106. Reynolds L, McKee M. Organised crime and the efforts to combat it: a concern for public health. Global Health. 2010;6:21. doi: 10.1186/1744-8603-6-21.
107. Chow CK, Corsi DJ, Gilmore AB, et al. Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries. BMJ Open. 2017;7:e013817. doi: 10.1136/bmjopen-2016-013817.
108. Miller V, Yusuf S, Chow CK, et al. Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet Glob Health. 2016;4:e695-e703. doi: 10.1016/S2214-109X(16)30186-3.
109. Stuckler D, McKee M, Ebrahim S, Basu S. Manufacturing epidemics: the role of global producers in increased consumption of unhealthy commodities including processed foods, alcohol, and tobacco. PLoS Med. 2012;9:e1001235. doi: 10.1371/journal.pmed.1001235.
110. Otite FO, Jacobson MF, Dahmubed A, Mozaffarian D. Trends in trans fatty acids reformulations of US supermarket and brand-name foods from 2007 through 2011. Prev Chronic Dis. 2013;10:E85. doi: 10.5888/pcd10.120198.
111. Colchero MA, Popkin BM, Rivera JA, Ng SW. Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study. BMJ. 2016;352:h6704.
112. Nelson JP, McNall AD. What happens to drinking when alcohol policy changes? A review of five natural experiments for alcohol taxes, prices, and availability. Eur J Health Econ. 2017;18:417-434. doi: 10.1007/s10198-016-0795-0.
113. Elder RW, Lawrence B, Ferguson A, Naimi TS, Brewer RD, Chattopadhyay SK, Toomey TL, Fielding JE; Task Force on Community Preventive Services. The effectiveness of tax policy interventions for reducing excessive alcohol consumption and related harms. Am J Prev Med. 2010;38:217-229. doi: 10.1016/j.amepre.2009.11.005.
114. Balabanova D, Mills A, Conteh L, et al. Good Health at Low Cost 25 years on: lessons for the future of health systems strengthening. Lancet. 2013;381:2118-2133. doi: 10.1016/S0140-6736(12)62000-5.
115. Institute of Medicine. In: Otten JJ, Pitzi Hellwig J, and Meyers LD, eds. Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington, DC: The National Academies Press; 2006. https://doi.org/10.17226/11537.